SNY - Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA European Medicines Agency Says | Benzinga
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has determined that there is no substantial evidence supporting a link between Glucagon-Like Peptide-1 receptor agonists (GLP-1) and suicidal or self-injurious thoughts and behaviors.
The assessment comes following reports of suicidal thoughts or actions. The FDA also conducted a review of GLP-1 RAs.
The FDA released an update stating that its preliminary review did not show definitive evidence that the drugs cause suicidal thoughts or actions.
GLP-1 receptor agonists, including dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide, are commonly prescribed for treating type 2 diabetes and, under specific conditions, for managing weight in obese or overweight adults.
The review was initiated ...